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 1 
INTRODUCTION 
  
Gene expression regulation  
  
Gene expression includes all the events that go from the transcription of a gene to the 
production of the corresponding protein. All these events are finely regulated. Studying 
gene expression means to understand in which tissue a gene is expressed, how it is 
expressed and what causes its expression. In fact, phenotypic differences among 
different cell types are mainly due to differences in gene expression patterns.  
Gene expression can be regulated at different levels: activation of DNA structure, start 
of transcription, maturation of the transcript, transport into the cytoplasm, translation of 
mRNA and protein stability. Nevertheless, the most important step is the start of the 
transcription process which determines whether a gene is transcribed or not. RNA 
polymerase II, as well as RNA polymerase I and III, needs proteins to find the right 
transcription start site and these proteins necessary for the start of the transcription 
process are called general initiation factors. Given that RNA polymerases and general 
initiation factors are the ultimate targets of regulatory events, during the assemblage of 
the RNA polymerases complex there are several points for regulation to take place. It is 
important to note that purified RNA polymerases and corresponding general initiation 
factors have an intrinsic ability to accurately transcribe DNA templates through core 
promoter elements, thus allowing the fundamental transcription mechanisms to be 
elucidated, but these activities are generally suppressed in the cell by the packaging of 
DNA within chromatin and by negative cofactors that directly interfere with the function 
of the basal transcription factors. As discussed below, this imposes requirements for 
transcriptional activators and corresponding cofactors that act in a gene-specific manner 
both to reverse the repression (antirepression) and to effect a net activation above the 
intrinsic activity of the basal transcription machinery.  
It is possible to subdivide transcriptional factors that cooperates directly with RNA 
polymerase II in three different categories: a) general transcription factors; b) upstream 
transcription factors; c) inducible transcriptional factors.  
a) General transcription factors are necessary for the start of RNA synthesis in all the 
genes of class II (genes that encodes for proteins). They form a complex with the RNA 
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polymerase II close to the transcription start site and this complex is called basal 
complex of transcription.  
b) Upstream transcriptional factors are proteins that recognize short consensus sequence 
situated upstream the transcription start site (an example is the Sp1 factor that recognizes 
GC boxes). These factors are ubiquitous and they act increasing the transcription 
efficiency of all the genes containing a GC box in their promoter.  
c) Inducible transcriptional factors work like upstream factors, but they have e 
regulatory role. They are synthesized or activated in a tissue-specific manner and they 
recognize sequences called response elements.  
In general, transcription factors acts directly recognizing specific and well conserved 
cis-sequences situated in promoters or enhancers. Some of these factors and of these 
sequences are common to more than a promoter and they are used in a constitutive 
manner; some other are specific and their activity is finely regulated. During the 
assembly process of these factors onto the regulatory sequences there are a lot of check- 
points and the speed of transcription can be increased or decreased in response to 
different regulatory signals. Nevertheless, not all the transcription factors bind these 
specific sequences on the promoter, they can also recognize other proteins already bound 
to the promoter, and sometimes they can bind directly to the RNA polymerase.  
Often DNA-binding factors that regulate the transcription of protein-coding genes act 
together with an expanding group of cofactors that act either through modifications of 
the chromatin structure or, more directly, regulating formation or function (transcription 
initiation or elongation) of the pre-initiation complex. Requirement for cofactors 
involved more directly in transcription is somewhat surprising in view of the specificity 
intrinsic to the various DNA-binding regulatory factors, the structural complexity of 
their ultimate target (the basal transcription machinery), and documented interactions 
between regulatory factors and components of the basal transcription machinery. Early 
studies of activator functions in systems reconstituted with DNA templates and purified 
RNA polymerase II and corresponding general initiation factors revealed that additional 
‘‘coactivator’’ or ‘‘mediator’’ activities were required for the activator function but not 
for basal (activator-independent) transcription.  
Coactivators functions in a variety of ways and often contain the enzymatic activities 
necessary for an alteration in chromatin structure from a quiescent state to one allowing 
active gene transcription. Broadly speaking, coactivators can be divided in three classes. 
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One class of proteins modifies histones in ways that allow greater access of other 
proteins to the DNA. Examples of these are p300 and CBP, powerful histone 
acetyltransferases (HATs) that interact with a wide variety of transcription factors and 
other proteins (Hermanson et al., 2002). These proteins support transcription in vitro 
from chromatinized templates. A second class of coactivators are members of the 
TRAP/DRIP/Mediator/ARC complex, proteins that bind to transcription factors, recruit 
RNA polymerase II and interact with the general transcription apparatus. The Mediator 
complex supports transcription in vitro from DNA templates but does not support 
efficient transcription from chromatinized templates. Lastly, protein complexes of the 
yeast SWI/SNF family (or their mammalian homologs BRG1 or BRM) contain ATP- 
dependent DNA unwinding activities, necessary for efficient gene transcription in vivo. 
These groups of proteins will not support transcription from naked DNA, but augment 
transcription from chromatinized templates in vitro (Lemon et al., 2001).   
Co-repressors have the opposite effect on chromatin  structure, making it unaccessible to 
the binding of transcription factors or resistant to their actions. These proteins (such as 
NcoR) are often associated with histone deacetylase (HDAC) activity, though other 
mechanisms for gene silencing clearly exist (Hermanson et al., 2002). Although 
coactivators are defined as proteins that increase transcriptional activity without binding 
to DNA, it is useful to think of those that bind directly to transcription factors and 
contain relevant enzymatic activities  as primary coactivators. Those that dock on 
transcription factors and serve as scaffolds for the recruitment of other proteins 
containing these enzymatic activities can be considered secondary co-activators. This 
distinction rapidly blurs as proteins that can function as primary coactivators on some 
transcription factors can also be used as enzymatic tools assembled by secondary 
coactivators in other contexts.  
 
 
TAZ (Transcriptional co-Activator with PDZ binding motif) 
 
TAZ, also referred to as Wwtr1 (WW-domain containing transcription regulator 1), is a 
transcriptional co-activator highly expressed in kidney, heart, lung, liver, testis, and 
placenta. TAZ is characterized by a central WW-domain followed by a highly conserved 
C-terminal sequence, which contains a coiled-coil domain that recruits core components 
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of the transcriptional machinery. Both human and mouse TAZ contain a single WW 
domain that is a very common domain that mediates protein-protein interaction. TAZ 
also contains a PDZ- binding motif at its C-terminus, that is required for its 
transcriptional coactivator activity and promotes TAZ nuclear localization particularly to 
discrete foci, and a 14-3-3 binding motif within the conserved N-terminal portion.  
   
 
 
 
 
 
 
 
 
 
 
 
How extracellular clues are transduced to the nucleus is a fundamental issue in biology. 
In this context, TAZ constitutes a transducer linking cytoplasmic signaling events to 
transcriptional regulation in the nucleus and the 14-3-3 binding is the key to this 
regulation.  Interaction of TAZ and YAP (the paralog of TAZ) with the phosphoserine 
and phosphothreonine-binding proteins 14-3-3 has been known for many years (Kanai et 
al. 2000; Vassilev et al. 2001; Basu et al. 2003). Hence, an important question is which 
kinases mediate the phosphorylation and link this event to dynamic signaling networks. 
Different groups have recently demonstrated that the fly Hippo pathway and the 
mammalian Hippo-like pathway play a key role in stimulating 14-3-3 interaction with 
the YAP/TAZ family of transcriptional coregulators.  
The fly protein Hippo is a Ste20 protein kinase that interacts with and is activated by the 
WW-domain protein Salvador. Upstream from Hippo there are different components, 
including Expanding and Merlyn, an atypical cadherin Fat, which localizes directly to 
the plasma membrane and the apical-basal polarity proteins (Crumbs complex). This 
component might link Hippo to extracellular clues. Particularly, the Crumbs complex 
(PALS1/LIN7C/PATJ) is a tight junction related component which localizes to the 
TAZ structure domain. TAZ contains WW domain, a 14-3-3 binding motif, a coiled-coiled 
motif in the transactivation domain and a PDZ-binding motif in the C-terminal. TB: Tead 
Binding Domain; TA: Transcriptional Activation Domain.  
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apical domain of polarized epithelial cells in high-density. Genetic studies in Drosophila 
have shown that Crb (Crumb, Crb) influences the Salvador/Warts/Hippo (SWH) 
pathway and tissue growth, by modulating the expression of Ex (Expanded, Ex) 
(Grzeschik et al. 2010; Robinson et al. 2010). The mechanism by which the Crumbs 
complex regulates TAZ activity in mammals is different from that in Drosophila. Both 
the WW-domain and the PDZ-binding motif are required for the interaction with 
PALS1, therefore, with the Crumbs complex. The knockdown of PALS1 or Crumb3 
decreases Ser89 phosphorylation levels and promotes nuclear localization of TAZ in 
high-density cells (Varelas et al. 2010).  
Downstream of Hippo are Warts/Lats and its activator Mats. Lats directly interact and 
phosphorilates Yorkie (the fly ortholog of YAP) and this phosphorylation stimulates 14-
3-3 binding to Yorkie and its nuclear export. A series of regulators form a signaling 
cascade to promote 14-3-3 binding and cytoplasmic localization of Yorkie, thereby 
controlling its transcriptional coactivator role. As illustrated in the figure below, these 
signaling regulators are conserved in mammals. The mammalian counterparts are FERM 
domain protein (FERM) 6, neurofibromatosis NF2, the Hippo-like kinases MSTs, the 
regulatory protein WW45, LATS kinases, and Mob1. As shown for Yorkie, LATS 
kinases phosphorylate YAP and TAZ to promote their 14-3-3 binding and subsequent 
nuclear export, thereby placing YAP and TAZ downstream of the Hippo-like pathway in 
mammals. Phosphorylation by LATS is multisite, with five sites on YAP and four sites 
on TAZ. The four sites on TAZ are analogous to the C-terminal four sites on YAP and 
three of the analogous sites are conserved in Yorkie but only one is required for 14-3-3 
binding, i.e. Ser89, in TAZ. 
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Apart from the Hippo-like pathway, growth factors such as bone morphogenetic protein 
2 (BMP-2) and fibroblast growth factor 2 (FGF-2) regulate TAZ expression and cell 
differentiation. In addition, through its WW domain, TAZ interacts with polyomavirus T 
antigens and this interaction induces nuclear accumulation of TAZ but inhibits its 
transactivation activity suggesting that nuclear localization of TAZ does not always 
correlate with its transactivation activity, and may thus have other roles (Tian et al. 
2004). TAZ has been defined as a “molecular rheostat” that modulates Mesenchymal 
stem cells (MSCs) differentiation (Hong et al. 2005). Two key transcription factors, 
Runx2 (also called Cbfa1 or Pebp2aA) and PPARγ, drive MSCs to differentiate into 
either osteoblasts or adipocytes, respectively, and the differentiation of each lineage 
appears to be mutually exclusive and transcriptionally controlled. TAZ interacts both in 
vitro and in vivo with Runx2 and this interaction leads to Runx2-stimulated osteocalcin 
gene expression. On the other hand TAZ interacts both in vitro and in vivo also with 
PPARγ but, in this case, it has been demonstrated that TAZ directly inhibit the ability of 
PPARγ to stimulate gene expression of the endogenous fatty acid-binding protein aP2, 
both in the presence or absence of the PPARγ-activating ligand Rosiglitazone. All 
Adapted from Chan et al. Journal of  Cellular Physiology 2011 
Comparison between Hippo pathway in fly (Drosophila melanogaster) and mammal. 
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together, these are evidence suggesting that TAZ acts as a transcriptional modifier of 
mesenchymal stem cell differentiation by promoting osteoblast differentiation while 
simultaneously impairing adipocyte differentiation.  
In the last years, a role of TAZ in the migration, invasion, and tumorigenesis of breast 
cancer cells has been outlined (Chan et al. 2008). In fact, the most highly invasive breast 
cancer cell lines express TAZ at levels that are approximately four times of those 
expressed by the majority of the weakly invasive breast cancer cells. The clinical 
relevance of this observation is supported by the finding that TAZ is overexpressed in a 
significant fraction of breast cancers (~21.4% of 126 commercially available breast 
cancer samples examined). Overexpression of TAZ in MCF10A cells (mammary 
epithelial cells) to a level ~2- to 3-fold of those detected in highly invasive cells caused a 
morphologic change from an epithelial to a fibroblast-like appearance an dramatically 
increased the migratory and invasive properties of the cells. Furthermore, shRNA-
mediated knockdown of TAZ expression in MCF7 (human breast adenocarcinoma cell 
line) and Hs578T (non-tumorigenic mammary cells able to form colonies in semisolid 
medium) cells reduced cell migration and invasion. The epithelial clusters of MCF7 cells 
became more densely packed with cells when TAZ expression was knocked down. 
These results indicate that TAZ is a negative regulator of epithelial 
morphology/architecture, as well as a positive regulator for invasive and migratory 
behavior. It is conceivable that TAZ overexpression in breast cancer may trigger the loss 
of epithelial property to promote migration. Moreover, when TAZ expression is knocked 
down in MCF7 cells, their anchorage-independent growth in soft agar and tumorigenesis 
in nude mice is retarded, suggesting that TAZ overexpression is an important part of the 
process involved in breast cancer development and progression. Recently, other two 
studies have connected TAZ overexpression with the development of the NSCLC (non-
small cell lung cancer, NSCLC) (Zhou et al. 2011) and PTC (papillary thyroid 
carcinoma, PTC) (de Cristofaro et al. 2011). TAZ is overexpressed in the NSCLC cell 
lines and knockdown TAZ significantly impaired the tumorigenic ability of the NSCLC 
cells (Zhou et al. 2011), but the NSCLC clinical samples should be explored in the 
future. The transcripts of TAZ from 61 samples of PTC were examined and found to be 
overexpressed significantly (de Cristofaro et al. 2011). 
Varelas et al. (Nature Cell Biology, 2008) described TAZ like a mediator of Smad 
nucleocytoplasmic shuttling that is essential for TGFβ signaling. In fact, although 
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TGFβ-dependent R-Smad phosphorylation and heteromeric complex formation occur in 
the absence of TAZ, nuclear accumulation of Smad complexes is lost. This results in 
loss of TGFβ-dependent signaling, which in hESCs (human Embryonic Stem Cells) 
results in the failure to maintain self-renewal markers. By modulating TAZ localization 
they demonstrated that TAZ dominantly controls the subcellular localization of the 
Smads. They further showed that the Mediator complex component ARC105 binds to 
and can retain TAZ in the nucleus. As TAZ itself shuttles in and out of the nucleus, these 
results support the existence of a hierarchical system that regulates the localization of 
Smad2/3 in the cell.  
In a recent study (Liu et al. 2010), TAZ was shown to regulate expression of the EMT 
transcription factor ZEB1 to control retinal pigment epithelial (RPE) cell proliferation 
and differentiation. ZEB1 expression is increased during RPE dedifferentiation, leading 
to cell proliferation and EMT. Interestingly, TAZ–TEAD1 translocation to the nucleus 
coincides with loss of cell–cell contact and onset of ZEB1 expression in the nucleus. 
Knockdown of TAZ by shRNA prevented the increased expression of ZEB1 and, in 
turn, prevented proliferation and EMT. TAZ was shown to bind to the ZEB1 promoter in 
vivo, suggesting that TAZ–TEAD complex may directly induce ZEB1 transcription to 
promote EMT and cell proliferation. TAZ may also function as a co- activator of MyoD 
to promote expression of target genes of MyoD to enhance myogenic differentiation 
(Jeong et al. 2010).  
Interestingly, it was recently shown that the Hippo pathway is able to restrict Wnt/beta-
Catenin signaling by promoting an interaction between TAZ and disheveled (DVL) in 
the cytoplasm. TAZ inhibits the CK1delta/epsilon-mediated phosphorylation of DVL, 
thereby inhibiting Wnt/beta-Catenin signaling. This study suggests that the cytoplasmic 
pool of TAZ may function to regulate Wnt signaling (Varelas et al. 2010).  
To date TAZ knock-out mice have been described in four papers (Hossain et al. 2006; 
Tian et al. 2007; Lei et al. 2008; Mitani et al. 2009). As mentioned before, TAZ was 
reported as a modulator of mesenchimal stem cell differentiation. Despite this, the 
staining of embryonic day 17.5 (E17.5) TAZ-/- mice embryos with Alcian blue and 
Alizarin red to reveal cartilage and bone tissue respectively, showed only minor skeletal 
abnormalities and knock-out mice present just a slightly smaller stature than wild type. 
Overall, the most relevant phenotypes described in TAZ null mice are severe polycystic 
kidney disease and lung emphysema. Signs of histological anomalies in TAZ-/- kidneys 
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were first apparent around E15.5 as dilations of the Bowman’s space between visceral 
podocytes and the parietal cell layer of the Bowman’s capsule. Pathological changes in 
TAZ-/- kidneys included parietal and tubular basement membrane thickening, thinning, 
and folding, and interstitial fibrosis and inflammation as evidenced by mononuclear 
leukocyte infiltration. TAZ-deficient mice have also emphysema-like features including 
enlarged air space and low elastance. The lungs of the Taz+/+ littermates developed 
normally from E16.5 to P14. At E18.5, the terminal bronchioles opened into a smooth-
walled channel dividing into several saccules. After the formation of the secondary septa, 
the saccules transformed into alveolar ducts and alveolar sacs lined with alveoli by the 
end of the alveolar stage. Once fully developed, Taz+/+ lungs showed a slight increase in 
alveolar space. Interestingly, most Taz-/- lungs grew normally until birth, whereas some 
embryos had smaller and immature lungs than their wild-type littermates. After birth, the 
terminal airways were in close proximity to the pleural surface with larger airspace by 
P5. Since then, although the number of saccules increased in proportion to the whole 
lung size, enlarged airspace in Taz-/-  lungs showed less alveolar compartmentalization 
than wild-type lungs, and the histological difference between Taz-/- and wild-type lungs 
became much clearer by 3 months. The alveoli of Taz-/- lungs showed a further small 
increase in size by 9 months. These mice exhibit abundant inflammatory cells in 
bronchoalveolar lavage fluid, evidence of chronic inflammation in lungs, and some 
TAZ-/- lungs have small focal areas with inflammatory changes (Mitani et al. 2009). 
Therefore, it looks like TAZ plays an important role in lung development, especially 
during the saccular and alveolar stages. 
 
 
 The Lung 
 
The major function of the lung is to excrete carbon dioxide from blood and replenish 
oxygen. The structure of the lung varies in complexity among vertebrate species but is 
highly conserved in its position along the foregut, ventral to the esophagus, between the 
thyroid and stomach.  
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Lungs are spatially organized along both cephalo-caudal (from the conducting airways 
to the peripheral saccules) and dorsal-ventral axes. The midline trachea develops two 
lateral outpocketings, the lung buds. Expression of transcription factors or markers 
characteristic of specific organs are observed along the anterior-posterior axis of the 
foregut tube before formation of each organ (Serls et al. 2005, Zorn A. M and Wells J. 
M.). TTF-1, an Nkx2 homeodomain-containing transcription factor, marks the region 
from which lung buds arise. As a general theme, many of the transcription factors 
required for development of the early foregut are reutilized later in lung morphogenesis 
(Zaret KS, 2002). For example, deletion of the Foxa2, Catnb, Sox17, Gata-6, Stat3 
genes, and other transcription factors expressed in endodermally derived cells along the 
foregut, results in failure of normal embryonic patterning well before the formation of 
the lung. Mammalian lungs are usually asymmetrically lobulated; for example, the 
mouse lung consists of four right and left main lobes. Pulmonary situs is determined by 
genes regulating left-right asymmetry (Raya et al. 2006). Formation of the lung also 
requires information that regulates right and left asymmetry and the gradual tapering of 
the conducting airways that lead to ever smaller tubes that lead to the alveoli where gas 
exchange occurs. The right lung bud eventually divides into three main bronchi, and the 
left into two main bronchi, thus giving rise to three lobes on the right and two on the left. 
Patterning of the foregut endoderm: lung bud 
formation and branching morphogenesis.  
 
 
 
Adapted from  Maeda et al. Physiol Rev 2007 
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The main right and left bronchi branch dichotomously, giving rise to progressively 
smaller airways, termed bronchioles, which are distinguished from bronchi by the lack 
of cartilage and submucosal glands within their walls. The bronchiolar epithelium is a 
simplified columnar epithelium made up of ciliated cells, a few basal cells and non-
ciliated secretory cells called Clara cells (Boers et al. 1999). More distally, the 
respiratory bronchioles are lined by a cuboidal epithelium comprised entirely of ciliated 
and Clara cells. Clara cells produce Clara cell secretory protein (also known as CCSP, 
CC10, CC16, Clara cell antigen, secretoglobin and uteroglobin), which is the most 
abundant secretory protein found in the airway surface fluid. Studies from CCSP knock-
out mice have shown that changes in CCSP levels have a profound impact on not only 
the composition of airway surface fluid but also the airway epithelial response to 
environmental stimuli (Stripp et al. 2002). Additional branching of bronchioles leads to 
terminal bronchioles; the part of the lung distal to the terminal bronchiole is called an 
acinus. Pulmonary acini are composed of respiratory bronchioles (emanating from the 
terminal bronchiole) that proceed into alveolar ducts, which immediately branch into 
alveolar sacs, the blind ends of the respiratory passages, whose walls are formed entirely 
of alveoli, the ultimate site of gas exchange. The microscopic structure of the alveolar 
walls (or alveolar septa) consists, from blood to air, of the following: 
- the capillary endothelium basement membrane and surrounding interstitial tissue 
separating the endothelium from the alveolar lining epithelium; 
- the pulmonary interstitium, composed of fine elastic fibers, small bundles of collagen, 
a few fibroblast-like cells, smooth muscle cells, mast cells, and rare mononuclear cells, 
is most prominent in thicker portions of the alveolar septum; 
- alveolar epithelium, which contains a continuous layer of two principal cell types: type 
II and type I alveolar epithelial cells that are in direct contact with respiratory gases, 
creating collapsing forces at the air-liquid interface. To maintain inflation, these surface 
forces are mitigated by the presence of pulmonary surfactant (a mixture of proteins and 
lipids) that is synthesized and secreted onto the alveolar surface by type II epithelial 
cells. Because pulmonary surfactant reduces surface tension, it is critical for the 
maintenance of lung volumes during the respiratory cycle. Lack of pulmonary surfactant 
in preterm infants with respiratory distress syndrome or adults with acute respiratory 
distress syndrome causes atelectasis leading to respiratory failure. The type II cell plays 
a critical role in surfactant production and in repair of the lung following injury, and it is 
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the progenitor cell for type I epithelial cells, which comprise the majority of the gas-
exchange region of the alveolus. It is increasingly clear that alterations in genes and 
processes affecting both type II cell homeostasis and surfactant function underlie the 
pathogenesis of a number of severe pulmonary diseases affecting infants, children, and 
adults, which, until very recently, were considered idiopathic. 
                    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The complexity of gene transcription during lung morphogenesis is immediately evident 
from the multiple cell types that comprise the lung, being derived from ectodermal, 
mesenchymal, and endodermal compartments, all present in appropriate numbers and 
sites to support respiration. Transcription factors uniquely specifying lung formation 
have not been identified to date. Although a number of transcription factors and their 
binding sites have been characterized and associated with the regulation of lung specific 
Microscopic structure of the alveolar wall. The basement membrane (yellow) is thin on one 
side and widened where it is continuous with the interstitial space. Portions of interstitial 
cells are shown. 
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genes, the principles that govern the design and evolution of transcriptional networks 
operating during lung formation and function have just begun to be understood. Not 
surprisingly, some of these genes encode proteins that are unique to the lung, namely, 
proteins critical for pulmonary surfactant homeostasis, which are required for reduction 
of surface tension at the air-liquid interface and without which gas exchange would not 
be possible.  
Study of lung-selective gene expression is relatively recent, beginning with the 
recognition that regulatory regions of all the surfactant protein genes, including Sftpa, 
Sftpb, Sftpc, and Sftpd, are controlled by the homeodomain containing protein thyroid 
transcription factor-1 (TTF-1; Nkx2.1) 
 
 
Surfactant proteins 
 
Pulmonary surfactant is a complex mixture of lipids, mostly phosphatidylcholine (PC), 
and associated proteins. Four of these surfactant proteins, designated SP-A, SP-B, SP-C, 
and SP-D, play critical roles in various aspects of surfactant structure, function, and 
metabolism (Perez-Gil et al. 2008). All four are expressed at relatively high levels in 
type II cells and have distinct structures and functions. Alveolar surfactant takes on 
discrete physical forms, including the abundant, highly ordered material called tubular 
myelin as well as multilamellated and smaller, vesicular, protein-lipid structures that can 
be isolated from the lung. Surfactant forms are determined by the presence or absence of 
surfactant proteins and lipids, by the physical forces generated during the respiratory 
cycle, and by selective processes mediating uptake or degradation. Surfactant 
multilayers, derived from highly lamellated and tubular myelin forms, spread over the 
surface of the alveolus and reduce surface tension. Surfactant components are recycled 
by type II cells or catabolized by alveolar macrophages in a highly regulated system that 
maintains precise levels of pulmonary surfactant throughout life. Both surfactant lipids 
and proteins are synthesized primarily by type II cells. Surfactant lipids are stored in 
large, lipid-rich, intracellular organelles, termed lamellar bodies. Lamellar bodies are 
rich in the surfactant-associated phospholipids, PC and phosphatidylglycerol (PG), and 
in two low-molecular-weight, hydrophobic surfactant proteins, SP-B and SP-C, that are 
cosecreted with the surfactant lipids and interact closely with them (Whitsett et al. 
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2002). 
SP-B and SP-C alter lipid packing and spreading and enhance the surface tension– 
lowering activity of the lipids, as well as stabilizing the lipid layers during the 
respiratory cycle. The surfactant proteins SP-A and SP-D are larger, relatively abundant, 
oligomeric proteins that are also synthesized and secreted by type II cells. SP-D and SP-
A are structurally related members of the collectin family of C-type mammalian lectins 
that share distinct collagen-like and globular, carbohydrate-binding domains. SP-A is 
required for the formation of tubular myelin and plays diverse roles in host-defense 
functions of the lung (Kingma et al. 2006; Wright 2005). SP-A binds 
lipopolysaccharides and various microbial pathogens, enhancing their clearance from the 
lung. Unlike SP-B and SP-C, SP-A does not play a critical role in surface functions, 
metabolism, or pulmonary surfactant under normal conditions. SP-D, however, 
influences the structural forms of pulmonary surfactant and is important in the regulation 
of alveolar surfactant pool sizes and reuptake (Korfhagen et al. 1998; Ikegami et al. 
2005). SP-D is also necessary in the suppression of pulmonary inflammation and in host 
defense against viral, fungal, and bacterial pathogens. Taken together, surfactant lipids 
and proteins play critical roles in (a) reducing surface tension in the alveolus, as required 
for ventilation, and (b) modulating various aspects of innate host defense of the lung 
against diverse pulmonary pathogens. 
 
 
TTF-1 
 
Thyroid transcription factor-1 (TTF-1, also termed T-EBP/Nkx2.1) is a member of the 
Nkx-2 class of homeodomain-containing transcription factors (Civitareale et al. 1989, 
Guazzi et al. 1990) that is selectively expressed in the developing thyroid, respiratory 
epithelium, and restricted areas of the developing brain (Lazzaro et al. 1991 – Minoo et 
al 1999). TTF-1 expression begins at the onset of thyroid and lung formation, and its 
expression is maintained in a highly regulated pattern in the thyroid follicular cells and 
subsets of respiratory epithelial cells (Boshart et al. 1992 - Zhou et al. 1996). In the 
thyroid, TTF-1 regulates thyroid-specific genes including thyroglobulin, 
thyroperoxidase, and the sodium-iodide symporter (Civitareale et al. 1989, Endo et al. 
1997, Francis-Lang et al. 1992). In the lung, TTF-1 activates the expression of surfactant 
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proteins A, B, C and D (SP-A, SP-B, SP-C and SP-D) and Clara cell secretory protein 
(Bruno et al. 1995 - de Felice et al. 2003). The critical role of TTF-1 for lung 
morphogenesis was shown in the study of TTF-1-null mice that lacked lung 
parenchyma, thyroid, and pituitary glands. TTF-null mice also have defects in the 
ventral area of the forebrain (Kimura et al. 1996, Minoo et al. 1999). Clinically, 
mutations in the human Ttf-1 gene result in central nervous system, thyroid, and 
respiratory disorders. Human TTF-1 haploinsufficiency has been linked to 
choreoathetosis, hypothyroidism, and various pulmonary disorders including neonatal 
respiratory distress and pulmonary infections (Krude et al. 2002). Transgenic mice in 
which TTF-1 is overexpressed in alveolar type II cells caused dose-dependent epithelial 
cell hyperplasia, emphysema, and pulmonary inflammation (Wert et al. 2002). Taken 
together, the temporal, spatial, and quantitative regulation of TTF-1 activity is critical 
for normal lung morphogenesis and physiology. TTF-1 binds an element termed the 
NKX binding element(s), containing 5′-TNAAGTG-3′, found in regulatory regions of 
target genes (Damante et al. 1994). Multiple NKX binding element(s) have been 
identified in the promoters of surfactant protein and Clara cell secretory protein genes 
(Bohinski et al. 1994, de Felice et al. 1995). These elements are required for the activity 
of the surfactant promoters. TTF-1 directly activated the promoters of target genes when 
expressed in non-respiratory epithelial cells. However, the mechanisms by which TTF-1 
regulates transcriptional activity on target promoters remain to be defined. TTF-1 
contains three distinct domains: an NH2-terminal transactivation domain, a DNA-
binding homeodomain, and a COOH-terminal activation domain. Structural and 
functional studies of TTF-1 NH2-terminal domain have suggested that the NH2-terminal 
domain has functional properties similar to the typical acidic activation domain in VP16 
(de Felice et al. 1995, Tell et al. 1998). The NH2-terminal domain was shown to mediate 
the primary transactivation activity because a TTF-1 mutant in which the NH2-terminal 
domain was deleted lost its transcriptional activity, whereas a mutant in which the 
COOH terminus of TTF-1 was deleted partially reduced activity (Ghaffari et al. 1997). 
Differences between the NH2-terminal and COOH-terminal activation domains of TTF-1 
were not observed when tested in the thyroglobulin promoter (de Felice et al. 1995, Di 
Palma et al. 2003). Thus, the NH2- and COOH-terminal domains may mediate 
interactions of TTF-1 with other proteins to regulate target gene expression in a gene-
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specific manner. Consistent with this concept, it is increasingly clear that TTF-1 
functions cooperatively with a number of other transcription factors, forming complexes 
on regulatory regions of target genes. TTF-1 interacts with Pax8, GATA6, STAT3, 
retinoic acid receptor and associated cofactors, nuclear factor-I (NFI-B), AP1 family 
members, and BR22 (Di Palma et al. 2003 – Yang et al. 2001). Recently it was been 
published that TTF-1 interacts with the transcriptional coactivator TAZ in the respiratory 
epithelial cells and this interaction brings to a more potent transcriptional activation of 
the SP-C promoter by TTF-1 (Park et al. 2004). 
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                                                      Aim of the project 
 
Transcriptional regulation is a fundamental process for cellular differentiation and 
development. In an adult organism differentiated cells are characterized by the 
expression of a specific subset of genes and this expression is regulated mainly at the 
transcriptional level. Study of lung-selective gene expression is relatively recent, 
beginning with the recognition that regulatory regions of all the surfactant protein genes, 
including Sftpa, Sftpb, Sftpc, and Sftpd, are controlled by the homeodomain containing 
protein thyroid transcription factor-1 (TTF-1; Nkx2.1). In recent years, different 
laboratories demonstrated that the Transcriptional co-Activator with PDZ-binding motif 
(TAZ) is involved in several pathways: from cell migration to proliferation, from 
molecular “rheostat” in Mesenchimal Stem Cell to promoter of invasion in breast cancer 
cells. Interestingly, it was been published that TTF-1 interacts with the transcriptional 
coactivator TAZ in respiratory epithelial cells and that this interaction brings to a more 
potent transcriptional activation of the SP-C promoter by TTF-1. 
An important contribution to the understanding of the physiological role of TAZ was 
given by several papers recently published in which TAZ-knockout mice were analyzed. 
The mice have major alterations in kidney and lung; in particular the kidney shows 
multicystic formations in the corticomedullary region similar to those found in cases of 
polycystic kidney syndrome in humans, while the lungs are greatly enlarged with 
impaired alveolarization, fibrosis and emphysema. 
As the transcriptional mechanisms mediated by TAZ are not yet clear, the aim of my 
study was to identify new partners of TAZ possibly involved in these phenotypes, using 
human lung cells. 
The identification and the characterization of such new partners might represent the 
basis for the elucidation of the molecular mechanisms underlying normal and abnormal 
lung development and to shed light on the pathogenesis of common human diseases. 
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RESULTS 
 
 Identification of the AMOTL2 protein as a TAZ-associated protein 
 
Preliminary, TAZ expression was examined by Western blot analysis of protein extracts 
prepared from H441 cells, HeLa cells and HeLa cells transiently transfected with an 
expression vector encoding TAZ, used as positive control. As shown in Fig. 1A, the 
polyclonal antibody that specifically recognizes TAZ reveals the presence of a protein of 
the predicted relative molecular mass in all the extracts analyzed. 
To identify proteins able to interact with the transcriptional coactivator TAZ in the lung 
environment, we challenged the GST–TAZ fusion protein, expressed in bacteria and 
affinity purified, with a total protein extract prepared from H441 human lung cells in a 
GST-pull down assay. To perform the GST-pull down in large scale,  200 mg of protein 
extract were pre-cleared onto GST-loaded beads and then divided into two tubes and 
incubated with GST and GST–TAZ loaded beads. Bound proteins were eluted, analyzed 
by SDS-PAGE and visualized by Coomassie blue staining. Several proteins bound 
specifically to the bait (Fig. 1B) and peptide mass fingerprint analysis, performed	   in 
collaboration with Dr. Andrea Scaloni of the ISPAAM-CNR of Naples, allowed us to 
obtain a list of possible interactors (Fig. 1C). Some of the identified proteins were 
already described as TAZ partners; interestingly, among the novel TAZ-interacting 
proteins there was the Angiomotin-like 2 protein (AMOTL2), which belongs to the 
Motin protein family (Bratt et al. 2002). Notably, AMOTL2 is on the top of the peptide 
hit list suggesting a strong interaction between AMOTL2 and TAZ. Angiomotin 
(AMOT), the founding member of the Motin family, is a vascular angiogenesis-related 
protein, which was initially identified as an angiogenesis inhibitor angiostatin-binding 
protein through a yeast two-hybrid screen (Troyanovsky et al 2001, Bratt et al. 2002). 
AMOT can induce endothelial cell migration and tubule formation and therefore 
promotes angiogenesis (Bratt et al. 2005). There are two angiomotin-like proteins, 
AMOTL1 and AMOTL2. Just like AMOT, AMOTL1 and AMOTL2 also play important 
roles in cell migration and angiogenesis (Gagnè et al. 2009, Huang et al. 2007), 
suggesting that this family of proteins may share similar functions in vivo.  
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Fig. 1: (A) TAZ is expressed in H441 human lung cells. Total protein extracts prepared from H441, 
HeLa and HeLa cells transiently transfected with CMV-TAZ were separated on SDS-PAGE and 
subjected to Western blot analysis with a specific anti-TAZ antibody. (B) To isolate cellular proteins 
interacting with GST–TAZ, glutathione-sepharose beads loaded with GST–TAZ or GST were 
incubated with total cell lysate obtained from H441, as described under Materials and Methods. After 
binding, the eluted proteins were separated on 8–15% SDS-PAGE and visualized by Coomassie blue 
staining. Lane 1, proteins eluted from GST beads. Lane 2, proteins eluted from GST–TAZ beads. 
Molecular weight markers are indicated on the left. (C) The table shows the number of peptide hits for 
AMOTL2 and several other TAZ-interacting proteins. 
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To confirm AMOTL2 as a TAZ-interacting protein, recombinant GST-TAZ protein was 
used in small scale GST pull-down experiments with total protein extracts prepared from 
lung and non-lung cells. In particular, we used the H441 cells as a source of lung-
specific protein extract and HeLa cells transiently transfected with an expression vector 
encoding for Amotl2 as a source of non-lung protein extract containing exogenous 
AMOTL2. Results of the binding reactions show that the AMOTL2 protein is 
specifically bound by GST-TAZ but not by the unfused GST protein (Fig. 2A). 
We then investigated whether the interaction described above could also be observed in 
vivo. To this end, 2 mg of total protein extract prepared from H441 cells were 
immunoprecipitated with the anti-TAZ antibody. The bound proteins were separated on 
10% SDS-PAGE and then analyzed by western blot with a polyclonal antibody 
recognizing AMOTL2. As shown in Fig. 2B, AMOTL2 was specifically co-
immunoprecipitated by the anti-TAZ antibody demonstrating that TAZ and AMOTL2 
co-exist in a complex in vivo. 
To obtain information on the subcellular distribution of TAZ and AMOTL2 in H441 
lung cells, we transiently transfected H441 with an expression vector encoding HA-
AMOTL2, and analysed their localization by indirect immunofluorescence. Confocal 
microscopy examination of dual-labelled samples confirmed that the anti-HA antibody 
stained the cytoplasm, and did not give any staining in the nucleus. At the same time, 
TAZ was detected both in the nuclear and in the cytoplasmic compartments; only in the 
latter it co-localized with AMOTL2. (Fig. 2C).  
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Fig. 2: (A) the GST-TAZ fusion protein immobilized on sepharose beads was incubated with total 
protein extracts prepareted from H441 human lung cells and from HeLa cells transiently transfected 
with an expression vector encoding AMOTL2. (B) in vivo interaction of TAZ with AMOTL2 revealed 
by co-immunoprecipitation in H441 cells. Immunoblotting was conducted using antibodies as indicated. 
(C) H441 cells were plated on glass coverslips and subsequently transfected with an expression vector 
encoding HA-tagged AMOTL2. At 48 h after transfection, cells were double-stained by 
immunofluorescence with a monoclonal anti-HA antibody and with a polyclonal anti-TAZ antibody. 
Fluorescein isothiocyanate and TRITC signals were acquired together at a confocal microscope, by 
line-wise scanning. The staining for AMOTL2 was detected only in the cytosol of the cells. TAZ 
staining was detected both in the nucleus and in the cytosol of the cells. The overlay of the signals is 
also shown.  
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The WW domain of TAZ and the PPXY motif of AMOTL2 mediate the protein-
protein interaction 
 
We next mapped the region responsible for TAZ and AMOTL2 interaction. It is reported 
in the literature that TAZ interacts with proteins containing a L/PPXY motif by means of 
its WW domain (Kanai et al. 2000), but also that it is able to interact with proteins 
lacking the above mentioned motif (Murakami et al. 2005). Therefore, to understand 
whether the WW domain of TAZ was the region of the protein responsible for the 
interaction with AMOTL2, we analyzed more in details the domains of TAZ involved in 
the binding with the protein. To this aim, we generated three GST-TAZ deletion mutants 
designated NW-TAZ, W-TAZ and C-TAZ, which preserve the N-terminal region and 
the WW domain (NW-TAZ) , only the WW domain (W-TAZ) or the C-terminal domain 
(C-TAZ) (Fig. 3A). Pull down experiments were performed using the fusion proteins 
GST-TAZ, GST-NW-TAZ, GST-W-TAZ and GST-C-TAZ, produced in bacteria and 
affinity purified, that were challenged with a protein extract prepared from HeLa cells 
transiently transfected with a vector encoding HA-AMOTL2. As shown in Fig. 3B, 
AMOTL2 is able to interact with full-length TAZ and also with NW-TAZ and W-TAZ 
deletion mutants but not with C-TAZ. The same experiment was performed also using a 
protein extract prepared from H441 cells in which the AMOTL2 is endogenously 
expressed at physiological levels (Fig. 3C). Bound proteins were detected by Western 
blot using a specific antibody against AMOTL2 while the hybridization with anti-GST 
antibody assessed the validity of the experiment and the protein uniform loading. 
To determine whether the interaction of AMOTL2 with TAZ occurs through the 
L/PPXY motif that is present in the N-terminal region of the protein, we used an 
expression vector encoding for the AMOTL2 mutated in the PPXY motif (Tyr213 to 
Ala). In addition, to investigate whether AMOTL2 contained other important regions 
involved in the binding with TAZ beyond the LPPY motif, we also analyzed a AMOTL2 
deletion mutant which is deleted of the PDZ binding domain present in the C-terminal 
region (Fig. 4A). 
To test whether the two mutants were still able to associate with TAZ, we performed 
pull down experiments with recombinant GST-TAZ and total extracts prepared from 
HeLa cells transiently transfected with the two mutants and the wild-type AMOTL2, 
separately. 
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Fig. 3: (A) Schematic representation of TAZ structure and of its deletion mutants used in 
GST-pull down assays. The NW-TAZ deletion mutant contains the entire N-terminal region 
and the WW domain; W-TAZ contains only the WW domain; C-TAZ contains the C-
terminal region downstream the WW domain. (B, C) GST-Pull down assays were performed 
with GST and GST-TAZ proteins immobilized on glutathione-sepharose beads and protein 
extract from HeLa transiently transfected with HA-AMOTL2 (B) and from H441 cells (C). 
Bound proteins were detected by Western blot using a specific antibody against AMOTL2 as 
indicated. The hybridization with anti-GST antibody assessed the validity of the experiment 
and the protein uniform loading. The asterisk indicates the full-length form of the fusion 
proteins.  
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The results of the GST-pull down experiments demonstrated that the mutation of the 
tyrosine residue in the PPXY motif  disrupts the interaction of AMOTL2 with TAZ. On 
the other hand, deletion of the PDZ-binding motif does not affect AMOTL2 interaction 
with TAZ (Fig. 4B). 
These results were also confirmed in vivo by co-immunoprecipitation assays. HeLa cells 
were transiently transfected with expression vectors encoding HA-AMOTL2 full-lenght, 
HA-AMOTL2-(ΔPDZ) and MYC-AMOTL2(Y213A) alone or in combination with 
3xFLAG-TAZ. As shown in Fig. 4C, HA-AMOTL2 and HA-AMOTL2-(ΔPDZ) were 
co-immunoprecipitated with 3xFLAG-TAZ while MYC-AMOTL2(Y213A) was not.  
All together the above results clearly demonstrate that the WW domain of TAZ and the 
PPXY motif of AMOTL2 play a major role in TAZ-AMOTL2 interaction. 
 
 
 
Fig. 4: (A) Schematic representation 
of AMOTL2 structure and of its 
mutants used in GST-pull down 
assays and in co-immuprecipitation 
assays. (B ) GST-Pull down assays 
were performed with GST and GST-
TAZ proteins immobilized on 
glutathione-sepharose beads and 
protein extract from HeLa cells 
transiently transfected with HA-
AMOTL2, HA-AMOTL2(ΔPDZ) 
and MYC-AMOTL2(Y213A).  
Bound proteins were detected by 
Western blot using a specific 
antibody against AMOTL2, as 
indicated. (C) In vivo interaction of 
TAZ with AMOTL2 revealed by co-
immunoprecipitation in HeLa cells 
transiently transfected with TAZ 
and HA-AMOTL2, HA-
AMOTL2(ΔPDZ) or MYC-
AMOTL2(Y213A). 
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AMOTL2 inhibits TAZ transactivation properties 
 
It has been published that TTF-1 interacts with the transcriptional coactivator TAZ in 
respiratory epithelial cells and that such interaction brings to a more potent 
transcriptional activation of the SP-C promoter by TTF-1 (Park et al. 2004). 
Hence, as next step we asked whether the interaction of TAZ with AMOTL2 could 
somehow affect the ability of TAZ to function together with TTF-1 in the modulation of 
SP-C gene expression. To investigate the functional outcome of the biochemical 
interaction between TAZ and AMOTL2, we performed luciferase assays using a reporter 
construct containing the TTF-1 responsive element identified in the promoter of the SP-
C gene (0.32 mSP-C-luc). HeLa cells transfected with the reporter construct and TTF-1 
showed a ∼sixfold increase over the basal level in the transcriptional activity of the SP-C 
promoter and co-transfection with TAZ resulted in a strong increase of TTF-1 
transcriptional activity on this promoter. Interestingly, when AMOTL2 was also co-
expressed in the same cells the ability of TAZ to enhance TTF-1 transcriptional activity 
on the SP-C promoter was significantly reduced (Fig. 5A). At the same time, the 
capability of TAZ to synergize with TTF-1 on the SP-C promoter was not affected by 
the co-expression with AMOTL2 mutated in the PPXY domain (Fig. 5B). Thus, our 
luciferase functional assays suggest that the biochemical interaction of AMOTL2 with 
TAZ inhibits the capability of TAZ to function as a transcripotional co-activator.  
 
 26 
        
 
 
 
 
 
 
 
Because AMOTL2 is a cytoplasmatic protein, whereas TAZ can shuttle between nucleus 
and cytoplasm, we investigated whether the observed inhibitory effect could be due to 
AMOTL2 sequestration of TAZ in the cytoplasm. To address this issue, HeLa cells were 
grown directly on glass coverslips and transiently transfected with TAZ and HA-
AMOTL2 or HA-AMOTL2-(Y213A). After 48 hours, cells were processed for double 
immunofluorescence analysis with a polyclonal anti-TAZ antibody and a monoclonal 
anti-HA antibody to follow the intracellular localization of the two proteins by confocal 
fluorescence microscopy. The signals from the two immunostained proteins were 
acquired together, at high resolution, by line-wise scanning. It is well-known that in low-
density HeLa cell cultures, TAZ is localized mainly in the nucleus. Interestingly, when 
we co-transfected TAZ together with AMOTL2, it was predominantly localized in the 
cytoplasm indicating that indeed TAZ subcellular localization is affected by the 
Fig. 5: (A-B) HeLa cells were transfected with 500 ng of a luciferase reporter construct 
carrying the TTF-1 responsive element of the SP-C promoter together with expression vectors 
encoding TTF-1, TAZ and AMOTL2 separately or in different combinations. Cells were also 
transfected with an expression vector for Renilla as an internal control. 
Cells were harvested after 48 h, and luciferase and renilla activities were measured.  The 
results are presented as fold increases in activity as compared with the control promoter alone. 
Values are mean of three independent experiments. 
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interaction with AMOTL2. In agreement with our previous data, TAZ  cellular 
distribution was not affected by the co-transfection with AMOTL2 mutated in the PPXY 
domain (Fig. 6A), supporting the relevance of the biochemical interaction between the 
two proteins for the modulation of TAZ cellular localization. To further strenghten these 
data, we co-transfected again HeLa cells plated on glass coverslips with the mutant 
TAZ-Ser89, in which the Ser89  phosphorylation site is mutated to Ala, together with 
AMOTL2 and we analyzed TAZ cellular distribution. Additionally, we were able to 
demonstrate that in such context AMOTL2 was still able to promote the cytoplasmic 
localization of TAZ-Ser89 suggesting that the mechanism by which AMOTL2 regulates 
the subcellular localization of TAZ is mediated by a direct protein-protein interaction 
and does not require TAZ phosphorylation at Ser89 site (Fig. 6B). 
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Subsequently, we were interested in the assessment of the role of AMOTL2 in the 
regulation of TAZ subcellular localization in a more physiological context. To this aim, 
H441 lung cells were transfected with 2 µg of the expression vector HA-AMOTL2 and 
48 hours after the transfection, selection with the specific antibiotic was started and ∼ 
forty independent clones were isolated. The over-expression of HA-AMOTL2 in the 
stable clones was examined by Western Blot analysis of protein extracts preparated from 
each clone. As shown in Fig 7A, the monoclonal antibody that specifically recognizes 
the HA tag revealed the presence of HA-AMOTL2 in three clones.  We further analyzed 
the subcellular localization of TAZ and AMOTL2 in the positive clones by indirect 
immunofluorescence followed by confocal fluorescence microscopy. Also in these 
experiments, the signals from the two immunostained proteins were acquired together, at 
high resolution, by line-wise scanning. As shown in figure 7B, the stable overexpression 
Fig 6: (A) TAZ was transfected in HeLa cells with or without co-transfection of HA-
AMOTL2 or MYC-AMOTL2-(Y213A). 48 h after transfection, cells were processed for 
double immunofluorescence analysis with polyclonal anti-TAZ antibody and monoclonal 
anti-HA antibody. (B) HeLa cells were co-transfected with GFP-TAZ-S89A and HA-
AMOTL2. 48 h after transfection, cells were processed for immunofluorescence analysis 
with the monoclonal anti-HA antibody. In both experiments, the signals from the two 
immunostained proteins were acquired together, at high resolution, by line-wise scanning. 
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of AMOTL2 in H441 cells induces a massive translocation of TAZ from the nucleus to 
the cytoplasm, as already observed in HeLa cells.  
 
 
 
 
 
 
 
 
 
 
 
Fig 7: (A) Total protein extracts prepared from each stable clones were separated on SDS-
PAGE and subjected to Western blot analysis with a specific anti-HA antibody. (B) One 
representative clone overexpressing HA-AMOTL2 was processed for double 
immunofluorescence analysis with polyclonal anti-TAZ antibody and monoclonal anti-HA 
antibody. The signals from the two immunostained proteins were acquired together, at 
high resolution, by line-wise scanning. 
HA-AMOTL2 
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DISCUSSION 
 
 
Transcriptional regulation is the most important way of modulating gene expression both 
in eukaryotes and in bacteria because it contributes to define the proteins expressed by a 
cell and, as a consequence, the functions characteristic of a cell. Specifically, this 
mechanism of regulation is more relevant in pluricellular organism where it allows a 
gene to be expressed in the right cell and at the right moment during development and 
differentiation.  
A pivotal role in transcriptional regulation is hold by transcription factors. We can 
define transcription factor any protein other than RNA Polymerase that is required for 
transcription. Transcription factors often don’t act alone but they are part of protein 
heterocomplexes in which they interact with different transcription factors, with 
accessories proteins and with transcriptional co-activators/repressors.   
TAZ (Transcriptional co-Activator with PDZ binding motif) is a transcriptional 
coactivator that, in these last years, has been described to interact with, and to regulate, 
several transcription factors (Murakami, et al. 2005; Murakami, et al. 2006; Mahoney, et 
al. 2005; Hong, et al. 2005; Park, et al. 2004). Moreover, it was suggested also a role of 
TAZ in migration, invasion and tumorigenesis of breast cancer cells and it has been 
demonstrated that  TAZ is overexpressed in a significant fraction of breast cancers (Siew 
Wee Chan, et al. 2008). Recently, other two studies have connected TAZ overexpression 
with the development of NSCLC (non-small cell lung cancer, NSCLC) (Zhou et al. 
2011) and PTC (papillary thyroid carcinoma, PTC) (de Cristofaro et al. 2011). TAZ is 
also a component of Hippo pathway in which the activation of TAZ leads to migration 
and cell proliferation (Zhang, et al. 2009). Studies from three independent laboratories 
have also shown that knockout of the TAZ gene in the mouse results in major defects in 
kidney and lung. In particular, the kidney shows multicystic formations in the 
corticomedullary region similar to those found in cases of polycystic kidney syndrome 
in humans, while the lungs are greatly enlarged with impaired alveolarization, fibrosis 
and emphysema. 
Summing up all the data present to date in the literature, TAZ turnes out to be a potent 
regulator of organ structure negatively regulated by the Hippo pathway. Hence, during 
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my Ph.D. I have been interested in identifying new partners of TAZ in human lung cells 
possibly involved in the lung phenotype observed in the knockout mouse. 
The lung is the essential respiratorian organ in many air-breathing animals. Its principal 
function is to transport oxygen from the atmosphere into the bloodstream, and to release 
carbon dioxide from the bloodstream into the atmosphere. Cellular differentiation in the 
lung is complex, and several morphologically distinct cell types comprise the airway 
epithelium. In particular, alveolar epithelium contains a continuous layer of two 
principal cell types: type II and type I alveolar epithelial cells. Preliminary data on the 
temporal/spazial expression pattern of TAZ in the developing mouse lung, demonstrated 
that TAZ mRNA is detectable from the embryonic stage E13.5 and at relatively high 
levels in purified mouse alveolar type II cells, which are known to express the 
transcription factor TTF-1 and the surfactan proteins (Stahlman et al. 1996, Zhou et al. 
1996, Liu et al. 2002). In this study, we identified through a GST-pull down assay 
followed by mass spectrometry analysis the Angiomotin-like 2 protein (AMOTL2) as a 
novel regulator of TAZ. AMOTL2 belongs to the Motin protein family that includes also 
Angiomotin (AMOT) and Angiomotin-like 1 (AMOTL1). Motin proteins have two 
coiled-coil domains and the C-terminal PDZ-binding motif in common and otherwise 
distinct domains, like a different number of PPXY motif. Angiomotin, the founding 
member of the Motin family, is a vascular angiogenesis-related protein, which was 
initially identified as a binding protein of angiostatin through a yeast two-hybrid screen, 
and it is able to regulate endothelial cell migration (Troyanovsky et al 2001, Bratt et al. 
2002).  Accordingly, also AMOTL1 is able to promote angiogenesis by controlling 
endothelial polarity and junction stability (Zheng et al. 2009).  
AMOTL2 has been studied in zebrafish embryos where it is expressed in blood vessels 
(Huang et al. 2007) and is required for angiogenesis. AMOTL2 is expressed maternally 
and in a restricted manner as soon as the zygotic genome begins to be expressed. 
Inhibition of zebrafish amotl2 expression by antisense morpholinos causes epiboly arrest 
and aberrant convergent extension in zebrafish embryos, which coincides with 
disruption of juxtamembrane actin fibers and formation of membrane protrusion. In vitro 
analyses reveal that zebrafish amotl2 regulates cell migration by binding to and 
promoting peripheral membrane translocation of the nonreceptor tyrosine kinase c-Src. 
In conclusion, these data suggest that amotl2 is essential for cell movement in vertebrate 
embryos, which might be associated with c-Src translocation. So, all three members of 
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Motin family are implicated in blood vessel formation, implying that they all have 
inherited this function from their common ancestor. However, they may have distinct 
functions in other cellular and developmental processes.  
It is reported in the literature that TAZ interacts with proteins containing a L/PPXY 
motif by means of its WW domain (Kanai et al. 2000), but also that it is able to interact 
with proteins lacking the above mentioned motif (Murakami et al. 2005). So in a first 
time, we mapped the regions responsible for TAZ and AMOTL2 interaction and 
demonstrated in vitro and in vivo that such interaction is mediated by the PPXY motif 
present in AMOTL2 protein and the WW domain present in the N-terminal region of 
TAZ.  
The numerous functions of TAZ described in the last years suggest that its availability 
and subcellular localization are tightly controlled to govern its functionality within the 
cell. The major known regulatory mechanism for TAZ is via the recently defined Hippo 
pathway. The Hippo pathway negatively regulates TAZ by two different mechanisms 
through cytoplasmic sequestration and proteasomal degradation. For these reasons, we 
investigated the effect of TAZ interaction with AMOTL2 on the transcriptional activity 
of TAZ. To this end, we used a luciferase report construct containing TTF-1 responsive 
elements identified in the SP-C promoter since the expression of  surfactant protein C is 
dependent on the cooperation of the transcription factor TTF-1 and TAZ. The results of 
the luciferase assays suggested an inhibitory role of AMOTL2 on TAZ ability to co-
activate transcription. We further demonstrated that such inhibition is due to the 
sequestration of TAZ in the cytoplasm induced by the intercation with AMOTL2. In 
fact, our immunofluorescence experiments clearly demonstrate that TAZ is detectable 
exclusively in the cytoplasm of the cells, both HeLa and H441, when co-transfected 
together with AMOTL2. In addition, our data also indicate that the delocalization of 
TAZ in the cytoplasm does not depend on its phosphorylation status, while is strictly 
correlated to the capability of TAZ to physically bind to AMOTL2. 
All together the results presented in this study offer an additional novel mechanism of 
regulation of the transcriptional co-activator TAZ which could take place through direct 
interaction with the AMOTL2 protein leading to the cytoplasmic sequestration of TAZ 
independently from the Hippo pathway-regulated interaction with 14-3-3 proteins. The 
general working model derived from our experiments is that AMOTL2 is primary 
cytosolic protein that is able to interact with TAZ through its PPXY motif and such 
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interaction causes the cytoplasmic sequestration of TAZ that consequently becomes 
incapable to exert its functions in the nucleus.  
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MATERIALS AND METHODS 
  
 
Plasmid constructs 
The plasmids used have been previously described and were as follows: GST-TAZ, 
CMV-TAZ and 0.32 mSP-C-luc (Park et al. 2004), GFP-TAZ-S89A (Kanai et al. 2000) 
and CMV-TTF-1 (Bohinski et al. 1994). The GST-TAZ-6HIS was generated by PCR 
amplification of TAZ coding region from pEF1A-TAZ-MYC-6HIS producted in our 
laboratory before and subsequent subcloning in the EcoRI-XhoI sites of the pGEX-4T3 
vector. The GST-NW-TAZ, GST-W-TAZ and GST-C-TAZ fusion proteins were 
generated by PCR amplification of the different portions of TAZ coding region and 
subsequent subcloning in the EcoRI-XhoI sites of the pGEX-4T3 vector. The 3xFLAG-
TAZ was generated by PCR amplification of mouse TAZ coding region and subcloned 
in the NotI-XbaI sites of the p3xFLAG-CMV10. HA-AMOTL2 full length and HA-
AMOTL2-(ΔPDZ) were kindly provided by S. sukita and MYC-AMOTL2-(Y213A) 
was kindly provided by J. Chen.  
 
Cell culture, transfections and reporter assays 
H441 cells were grown in RPMI medium (Euroclone) supplemented with 10% fetal 
bovine serum. For stable transfection of pCAGGS-HA-AMOTL2, H441 cells were 
cultured in 100mm plates and transfected with 2µg of DNA with the addition of 200ng 
of pBABE-puro. After 48h from transfection selection with the specific antibiotic was 
started. 0.4 µg/ml puromycin (Sigma) was used to select clones. HeLa cells were grown 
in Dulbecco's modified Eagle's medium (Euroclone) supplemented with 10% fetal calf 
serum (Hyclone). For transient transfection experiments, cells were plated at 3×105 
cells/60-mm tissue culture dish 5 to 8 h prior to transfection. Transfections were carried 
out with the FuGENE6 reagent (Roche Diagnostics) according to the manufacturer's 
directions. The DNA/FuGENE ratio was 1:2 in all the experiments. The reporter 
construct 0.32 mSP-C-luc was co-transfected with expression vectors encoding 
transactivators TTF-1 and TAZ and HA-AMOTL2 or HA-AMOTL2-(Y213A). Firefly 
Luciferase activity was normalized on the activity of pRL-Renilla vector in order to 
correct each sample for transfection efficiency. The total amount of transfected DNA 
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was kept constant with an empty expression vector in all the transfection assays. 
Luciferase assay and Renilla assay were performed using the Luciferase Assay System 
(Promega) and the Renilla Luciferase Assay System (Promega) following the instruction 
of the manufacturer. Protein extraction was performed using the Passive lysis buffer 
(Promega) supplemented of protease inhibitors (100X protease inhibitor cocktail, 
SIGMA). Luminescence was measured with LUMAT LB 9507 luminometer (Berthold 
technologies).Transfection experiments were done in duplicate and repeated at least 
three times. Statistical analysis has been performed by means of an unpaired two-tailed 
Student's t test to obtain the P value associated with the observed fold of activation 
differences. 
 
Protein extracts and immunoblotting 
For Western blot, cells were washed twice with ice-cold phosphate-buffered saline 
(PBS) and lysed in JS buffer containing 50 mM Hepes pH 7.5, 150 mM NaCl, 5 mM 
EGTA pH 7.8, 10% glycerol, 1% Triton, 1.5mM MgCl2, 1 mM dithiothreitol (DTT), 1 
mM phenylmetilsulfonil fluoride (PMSF). The protein concentration was determined 
using the Bio-Rad protein assay (Bio-Rad Laboratories, Inc., Hercules, CA). For 
Western blot analysis, proteins were separated by SDS-10% PAGE, gels were blotted 
onto Immobilon P (Millipore, Bredford, MA, USA) for 2 h and the membranes were 
blocked in 5% nonfat dry milk in Tris-buffered saline for 1 h or overnight before the 
addition of the antibody for 1 h. The primary antibodies used were anti-TAZ (kindly 
provided by M. Sudol), anti-AMOTL2 (kindly provided by), anti-Myc (Santa Cruz, 
CA), anti-HA (Covance), anti-FLAG (Sigma), anti-GST (kindly provided by P. Di 
Fiore). The filters were washed three times in Tris-buffered saline before the addition of 
horseradish peroxidase-conjugated secondary antibodies for 45 min. Horseradish 
peroxidase was detected with ECL (GE Healthcare). 
 
Pull down assay and co-immunoprecipitation 
GST–TAZ and deletion mutants proteins were purified from BL21 (DE) LysS bacterial 
cells transformed with pGEX-TAZ, pGEX-NWTAZ, pGEX-WTAZ and pGEX-CTAZ. 
At D600 = 0.6, isopropyl β-D- thiogalactoside (0.1 mM final) was added to the culture 
to induce the expression of the fusion protein, and cells were harvested 4 h later. Cells 
were resuspended in lysis buffer (1 × PBS, 0.5 mM EDTA, 1 mg/ml lysozyme, 0.5 mM 
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dithiothreitol, 1 mM PMSF and protease inhibitors diluted 1:1000), and sonicated. 
Triton X-100 (1 %, v/v) was then added, and the cell extract was centrifuged at 200 000 
g for 40 min at 4 ◦ C. The supernatant was subjected to affinity chromatography using 
glutathione–agarose beads (Amersham-Pharmacia). After binding, beads were washed 
three times with washing buffer (10 mM Tris/HCl, pH 8.0, 100 mM NaCl, 5 mM EDTA, 
5 mM dithiothreitol). GST–TAZ and deletion mutant proteins were eluted with a  buffer 
containing 10 mM glutathione, 50 mM Tris/ HCl, pH 8.0, and 50 mM NaCl for 10 min 
at 4 ◦C. The eluted proteins were stored at − 80 ◦C. Pull-down assays were performed by 
challenging 4 µg of GST or GST–TAZ, GST–NWTAZ , GST–WTAZ or GST–CTAZ 
purified proteins bound previously to glutathione–agarose beads with proteic extract 
from H441 or HeLa cells transiently transfected with HA-AMOTL2, HA-AMOTL2-
(ΔPDZ) or MYC-AMOTL2-(Y213A). The binding reactions were carried out for 90 min 
at 4 ◦C on a rotating wheel, and then the beads were washed several times with JS 
buffer. The bound proteins were eluted by resuspending the beads directly in 2 × 
SDS/PAGE sample buffer and heating at 95 ◦C for 3–5 min before loading on the gel. 
To analyze the interaction of TAZ with AMOTL2, a construct expressing 3xFLAG-TAZ 
was transfected into HeLa cells alone or with vectors encoding HA-AMOTL2, HA-
AMOTL2-(ΔPDZ) or MYC-AMOTL2-(Y213A). About 48 h after transfection, cells 
were washed twice with PBS and lysed in JS buffer. The co-immunoprecipitation 
experiment was performed by incubating 2 mg of total protein extract with 20 µl of anti-
FLAG agarose affinity gel (Sigma) overnight at 4 ◦C on a rotating wheel. The samples 
were then centrifuged and the agarose gel-bound proteins were washed several times 
with JS buffer, resuspended in 2 × SDS/PAGE sample buffer and heated at 95 ◦C for 3–
5 min before loading on the gel. The same conditions were used when the 
coimmunoprecipitation experiment was performed using H441 cells. 
 
Protein identification by mass spectrometry 
GST and GST–TAZ-6HIS proteins, purified from BL21 (DE) LysS bacterial cells as 
described before, were loaded onto glutathione–Sepharose beads (GE Healthcare, 
Waukesha, WI, USA) at a concentration of 1 µg/µl packed beads for 20 min at 4 °C. 
A total of 5×108 H441 cells were lysed; after a pre-clearing step on  GST-coated beads, 
the total extract was adsorbed with GST and GST–TAZ-6HIS beads. After washing, the 
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bound proteins were resolved by SDS-PAGE, and visualized by comassie blue staining. 
For identification, protein bands were excised from the gel, triturated, in-gel S-alkylated 
and digested with trypsin as previously reported (Caratu et al. 2007, Vascotto et al. 
2007). Gel particles were extracted with 25 mM NH4HCO3/acetonitrile (1:1 v/v) by 
sonication. Samples were desalted using microZipTipC18 pipette tips (Millipore, 
Bredford, MA, USA) before MALDI-TOF-MS analysis. Peptide mixtures were loaded 
on the MALDI target together with a-cyano-4-hydroxycinnamic acid as matrix, using 
the dried droplet technique. Samples were analyzed with a Voyager-DE PRO 
spectrometer (Applera, Foster City, CA, USA; Caratu et al. 2007, Vascotto et al. 2007). 
Mass spectra were acquired in reflectron mode; internal mass calibration was performed 
with peptides from trypsin autoproteolysis. Data were elaborated using the DataExplorer 
5.1 software (Applera, USA). ProFound software (Zhang & Chait 2000) was used to 
identify protein bands from an NCBI non-redundant database using peptide mass 
fingerprint data. Candidates with program Est'd Z scores more than 2 were further 
evaluated by comparison with Mr experimental values obtained from SDS-PAGE. 
Eventual occurrence of protein mixtures was ascertained by sequential searches for 
additional protein components using unmatched peptide masses.  
 
Indirect immunofluorescence and confocal scanning laser microscopy 
HeLa and H441 cells were plated and cultured on 12 mm diameter glass coverslips 24 to 
48 h prior to transfection with FuGENE6 reagent. Transfections were performed with 
500 ng of each plasmid used and DNA/FuGENE ratio was 1:2 in all the experiments. 
Twenty-four hours after transfection, cells were fixed for 20 min at room temperature 
with a 4% solution of paraformaldehyde in PBS, treated for 20 min with 50 mM solution 
of NH4Cl in PBS, permeabilized for 5 min with a 0.5% solution of Triton X-100 in PBS 
and incubated for 60 min in 1% BSA in PBS. The coverslips were subsequently 
incubated for 60 min at room temperature with primary antibodies diluted in 0.5% BSA 
in PBS. After PBS washings, the coverslips were incubated for 30 min with Alexa 594-
tagged goat anti-rabbit, and Alexa 488-tagged goat anti-mouse secondary antibodies 
diluted 1:70 in 0.5% BSA in PBS. After final washings with PBS, the coverslips were 
mounted on a microscope slide using a 50% solution of glycerol in PBS. 
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Primary antibodies were rabbit polyclonal anti-TAZ (kindly provided by M. Sudol), 
anti-c-Myc (9E10) monoclonal antibody from Santa Cruz Biotechnology, Inc. (Santa 
Cruz, CA, U.S.A.) and anti-HA from COVANCE. Confocal scanning laser microscopy 
images were collected with a Zeiss LSM 510 confocal laser scanning microscope, 
equipped with a 543 nm HeNe laser, a 488 nm argon ion laser and a Plan-Apochromat 
63×/1.4 oil-immersion objective. Emitted fluorescence was detected using a BP 505–530 
bandpass filter for Alexa Fluor 488 and a LP 560 long pass filter for Alexa Fluor 594. 
Pairs of images were collected simultaneously in the green and red channels. High 
magnification images were collected as 1024×1024×32 voxel images.      
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